Harrow Health, Inc. 8.625% Senior Notes due 2026 (HROWL)

Harrow Health, Inc. 8.625% Senior Notes due 2026 (HROWL) Healthcare & Pipeline Overview

Harrow Health, Inc. (HROWL) specializes in developing and marketing innovative medications, primarily through its ImprimisRx compounding business. With a focus on addressing unmet patient needs, Harrow operates within the competitive medical pharmaceuticals sector, balancing growth initiatives with profitability challenges reflected in its negative profit margin.

What Is the Investment Thesis for HROWL?

Harrow Health presents a mixed investment thesis. While the company boasts a high gross margin of 75.1%, its negative profit margin of -1.9% raises concerns about profitability. The company's focus on specialized medications and the ImprimisRx compounding business offer potential growth avenues. Upcoming catalysts include potential FDA approvals for new drug formulations and expansion into new therapeutic areas. However, investors should be aware of the risks associated with pharmaceutical development, including regulatory hurdles and competition from established players. The company's beta of 0.14 suggests relatively low volatility compared to the broader market. Monitoring the company's progress in achieving profitability and successfully commercializing its drug pipeline is crucial for assessing its long-term investment potential.

Based on FMP financials and quantitative analysis

HROWL Key Highlights

• Market capitalization of $1.37 billion, reflecting investor valuation of Harrow's potential in the pharmaceutical market.
• Gross margin of 75.1%, indicating strong pricing power and efficient production processes.
• Negative P/E ratio of -249.15, due to current losses, suggesting the company's earnings are not yet supporting its valuation.
• Beta of 0.14, indicating lower volatility compared to the overall market, potentially appealing to risk-averse investors.
• Operates through two segments: Pharmaceutical Compounding and Pharmaceutical Drug Development, diversifying its revenue streams and growth opportunities.

Who Are HROWL's Competitors?

HROWL is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are HROWL's Key Strengths?

• Specialized medication focus.
• Established ImprimisRx business.
• Innovative drug development pipeline.
• High gross margin.

What Are HROWL's Weaknesses?

• Negative profit margin.
• Reliance on compounding pharmacies.
• Limited market share compared to larger pharmaceutical companies.
• Dependence on regulatory approvals.

What Could Drive HROWL Stock Higher?

• Potential FDA approval of new drug formulations, expanding the company's product offerings.
• Expansion of the ImprimisRx compounding business, increasing revenue and market reach.
• Strategic acquisitions and licensing agreements, adding new products and technologies to the portfolio.
• Geographic expansion into new markets, tapping into new patient populations.

What Are the Key Risks for HROWL?

• Negative return on equity (-33.7%) — the business is not currently generating profit on shareholder capital.
• Insider selling — insiders were net sellers of roughly $7.6M recently.
• Regulatory hurdles and compliance requirements, delaying or preventing drug approvals.
• Competition from larger pharmaceutical companies, impacting market share and pricing.
• Negative profit margin, raising concerns about financial sustainability.
• Product liability risks, leading to costly lawsuits and reputational damage.
• Dependence on compounding pharmacies, creating reliance on third-party distribution.

What Are the Growth Opportunities for HROWL?

• Expansion of ImprimisRx Business: The ImprimisRx compounding business represents a significant growth opportunity for Harrow. By expanding its network of compounding pharmacies and developing new customized formulations, Harrow can cater to a growing demand for personalized medications. The market for compounded medications is estimated to reach several billion dollars, offering substantial revenue potential. This expansion could involve strategic partnerships with healthcare providers and pharmacies, as well as investments in research and development to create innovative formulations. The timeline for this growth is ongoing, with continuous efforts to expand the ImprimisRx network and product offerings.
• FDA Approval of New Drug Formulations: Securing FDA approval for new drug formulations represents a major growth catalyst for Harrow. Successful approval and commercialization of new drugs can generate significant revenue streams and enhance the company's reputation. The market size for each approved drug will depend on the specific therapeutic area and patient population. The timeline for FDA approval can vary, but typically involves several years of clinical trials and regulatory review. This growth opportunity requires significant investment in research and development, as well as a strong regulatory strategy.
• Strategic Acquisitions and Licensing Agreements: Harrow can pursue growth through strategic acquisitions and licensing agreements. Acquiring or licensing existing medications can expand the company's product portfolio and market reach. The market size for acquired or licensed products will depend on their specific indications and market penetration. The timeline for acquisitions and licensing agreements can vary, but typically involves due diligence, negotiation, and regulatory approvals. This growth opportunity requires careful selection of targets and effective integration of acquired assets.
• Geographic Expansion: Expanding into new geographic markets represents another growth opportunity for Harrow. By entering new regions, the company can tap into new patient populations and revenue streams. The market size for each new geographic market will depend on the local healthcare system and regulatory environment. The timeline for geographic expansion can vary, but typically involves market research, regulatory approvals, and establishment of distribution networks. This growth opportunity requires careful planning and execution to ensure successful market entry.
• Development of Novel Drug Delivery Systems: Investing in the development of novel drug delivery systems can provide a competitive advantage for Harrow. By creating innovative ways to administer medications, the company can improve patient outcomes and enhance the value of its products. The market size for novel drug delivery systems is growing, driven by the demand for more convenient and effective treatments. The timeline for developing new drug delivery systems can vary, but typically involves several years of research and development. This growth opportunity requires significant investment in innovation and collaboration with research institutions.

What Opportunities Does HROWL Have?

• Expansion into new therapeutic areas.
• Strategic acquisitions and licensing agreements.
• FDA approval of new drug formulations.
• Geographic expansion into new markets.

What Threats Does HROWL Face?

• Competition from larger pharmaceutical companies.
• Generic competition and pricing pressures.
• Regulatory hurdles and compliance requirements.
• Product liability risks.

What Are HROWL's Competitive Advantages?

• Specialized formulations cater to niche markets.
• Proprietary drug development pipeline.
• Established ImprimisRx compounding network.
• Strong relationships with healthcare providers.

What Does HROWL Do?

Harrow Health, Inc., founded in January 2006 by Mark L. Baum and Robert J. Kammer, is a pharmaceutical company focused on developing, producing, and selling specialized medications. Headquartered in Nashville, Tennessee, Harrow operates through two primary segments: Pharmaceutical Compounding and Pharmaceutical Drug Development. The Pharmaceutical Compounding segment is largely driven by the ImprimisRx business, which focuses on providing customized medications to meet specific patient needs. This segment leverages compounding pharmacies to create formulations that are not readily available through traditional pharmaceutical manufacturers. The Pharmaceutical Drug Development segment is dedicated to creating and commercializing novel pharmaceutical products. Harrow's strategy involves identifying gaps in the market and developing innovative solutions to address these unmet needs. The company's approach includes both developing its own proprietary products and acquiring or licensing existing medications to expand its portfolio. Harrow aims to provide affordable and accessible medications to patients while driving long-term growth and shareholder value. The company's focus on innovation and customization differentiates it within the competitive pharmaceutical landscape.

What Products and Services Does HROWL Offer?

• Develop innovative medications to address unmet patient needs.
• Produce specialized medications through pharmaceutical compounding.
• Operate the ImprimisRx business, focusing on customized medications.
• Engage in pharmaceutical drug development to create novel products.
• Commercialize medications through various distribution channels.
• Acquire or license existing medications to expand their portfolio.
• Cater to specific patient needs with customized formulations.

How Does HROWL Make Money?

• Develop and manufacture specialized medications.
• Generate revenue through sales of compounded and branded pharmaceuticals.
• Partner with compounding pharmacies to distribute ImprimisRx products.
• Acquire or license existing drug products to expand portfolio.

What Industry Does HROWL Operate In?

Harrow Health operates within the medical pharmaceuticals industry, a sector characterized by intense competition, stringent regulatory requirements, and high research and development costs. The industry is driven by innovation, with companies constantly seeking to develop new and improved treatments for various medical conditions. Harrow's focus on specialized medications and compounding positions it within a niche market, allowing it to cater to specific patient needs. The pharmaceutical market is experiencing growth, driven by an aging population and increasing healthcare spending. However, companies like Harrow face challenges such as generic competition and pricing pressures. Competitors include companies like AGTI, BKD, CINC, CTIC, and FNA, each vying for market share in various segments of the pharmaceutical industry.

Who Are HROWL's Key Customers?

• Patients requiring customized medications.
• Healthcare providers seeking specialized treatments.
• Pharmacies that compound and dispense medications.
• Hospitals and clinics utilizing specialized pharmaceuticals.

Company Profile

Harrow Health, Inc. 8.625% Senior Notes due 2026 operates in the Medical - Pharmaceuticals industry within the Healthcare sector. It is headquartered in Nashville, US. The company is led by CEO Mark L. Baum. HROWL has traded publicly since 2021.

How Harrow Health, Inc. 8.625% Senior Notes due 2026 Is Valued

Relative to its peer group, HROWL's quantitative score of 51/100 is roughly in line with the peer average of 50/100.

ROE -34%Key Financial Metrics

Return on equity for Harrow Health, Inc. 8.625% Senior Notes due 2026 stands at -33.7%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -3.6%, showing how much profit it generates from its asset base. Its free cash flow yield is 0.9%, a gauge of the cash the business throws off relative to its market value. A current ratio of 2.48 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -0.9%, the inverse of the P/E and a quick read on earnings relative to price.

F-Score 6/9Financial Health

Harrow Health, Inc. 8.625% Senior Notes due 2026's Piotroski F-Score is 6/9, a 9-point checklist of profitability, leverage and efficiency — a middling fundamental profile. Its Altman Z-Score of 3.12 places it in the safe zone, indicating low near-term bankruptcy risk.

FY2026 estForward Outlook

Wall Street analysts project Harrow Health, Inc. 8.625% Senior Notes due 2026 revenue of about $397.7M for fiscal 2026, with EPS near $1.79.

Net sellingInsider Activity

Over the past six months, Harrow Health, Inc. 8.625% Senior Notes due 2026 insiders filed 12 SEC Form 4 transactions — 5 sales and 7 purchases. On net that is roughly 138K shares disposed (about $7.6M), a signal worth weighing alongside the fundamentals.

HROWL Financials

HROWL Latest News

No recent news available for HROWL.

HROWL Analyst Consensus

HROWL MoonshotScore

Common Questions About HROWL (Healthcare)

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources